TTR and cardiac amyloidosis: The inclusion criteria were as follows: (i) randomized controlled trials (RCTs), non-RCTs, or single-arm studies of Tafamidis that included patients with transthyretin amyloid cardiomyopathy, either wild-type or variant-type; (ii) studies done on patients of any race and age 18 years or above; (iii) studies with the following outcomes: TTR stabilization, cardiac biomarkers, ECG or Holter parameters, echocardiographic parameters, functional tests, quality of life, arrhythmias, hospital admission, and death; (iv) studies published in the English language.